Drugs / SH229
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03748745 | Nov → Dec 2018 | — | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03588923 Comparator | Jul → Aug 2018 | hepatitis C virus infection | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-09-30 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Results 圣和药业“和乐布韦（SH229）片II/III期临床试验期中分析会”圆满召开 sanhome.com ↗
同时，各位专家纷纷建言献策、给出专业意见，并一致建议本项目尽快进入III期临床研究，期待和乐布韦（SH229）片能早日进入市场造福患者。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-09-30 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 圣和药业“和乐布韦（SH229）片II/III期临床试验期中分析会”圆满召开 sanhome.com ↗ |
| 2019-02-19 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 圣和药业“和乐布韦（SH229）片II/III期临床试验研究者会”圆满召开 sanhome.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SH229 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03748745 ↗ |
| Route | Oral | “tablet, oral, 400 mg once daily for 3 days” NCT03588923 ↗ |